Skip to main content
SpringerPlus

Table 3 Selected demographic and baseline characteristics of the patients grouped by reason for dose reduction

From: Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience

Categorical factor

Dose reduction due to other reasons (N=28)

CIPN dose reduction (N=21)

p-value1

 

N(row%)

N(row%)

 

Her2

   

Negative

22 (58)

16 (42)

1.00

Positive

6 (55)

5 (45)

 

Agent

   

Paclitaxel only

4 (22)

14 (78)

0.001 2

Docetaxel only

20 (80)

5 (20)

 

Multiple agents3

4 (67)

2 (33)

0.68

Alcohol

   

No

27 (57)

20 (42)

1.00

Yes

1 (50)

1 (50)

 

Diabetes

   

No

22 (61)

14 (39)

0.51

Yes

6 (46)

7 (54)

 

Race

   

Black

14 (47)

16 (53)

<0.001 4

White

14 (78)

4 (22)

 

Other

0

1 (100)

 

Continuous Factor

Mean (range)

Mean (range)

 

Age (years)

55 (42–75)

55 (35-67)

0.84

  1. 1p-values calculated with the use of two-sided Fisher’s and Fisher-Freeman-Halton’s tests for categorical variables and the t-test for continuous variables.
  2. 2Patients treated with paclitaxel (or nab- paclitaxel) only vs. those treated with docetaxel only.
  3. 3Patients treated with multiple agents, compared to those treated with either paclitaxel only or docetaxel only.
  4. 4Black compared to white only.
Back to article page